A press announcement authorizing a COVID-19 vaccine to be distributed to target a group of variants that includes the Omicron variant still results in a market that results to Yes, as would an approval of a change in the dosage amount specifically to target variants including the Omicron variant. The authorization can be restricted to a subset of individuals in the U.S. and still resolve to Yes. Else, the market resolves to No.

Please see OMIVAX in the Rulebook for the complete legally binding terms and conditions. If the event occurs early, then the market will close and expire one day following the occurrence of the event.

CLARIFICATION AS OF 31-Jan-2022 at 1:40 PM ET: An authorization of a vaccine that targets COVID-19 without specifically targeting Omicron (or a group of variants including Omicron) is not encompassed in the Payout Criterion. For example, upgrading an emergency use authorization approved before the existence of Omicron to a full authorization without modification would not result in the contract resolving to Yes, even if that vaccine does protect against variants including Omicron, as that vaccine is neither "distributed specifically to target the Omicron variant" nor "distributed to target variants including the Omicron variant".